Global Primary Cells Market
The Primary Cells Market is witnessing remarkable growth, driven by the increasing adoption of primary cell culture techniques. Primary cell culture involves the isolation and cultivation of cells directly from living tissue, preserving their physiological characteristics and biological functions. This technique enables researchers to study cellular behavior in vitro more accurately, reflecting the complexities of tissues in vivo. Primary cell culture models serve as invaluable tools for investigating cellular mechanisms, disease pathology, and drug response, facilitating advancements in biomedicine and drug discovery. With a growing demand for physiologically relevant cell models, the Primary Cells Market continues to expand, offering researchers a diverse array of primary cell types for various applications.
Market Research Future (MRFR) reports that the Primary Cells Market Size was valued at USD 0.6 billion in 2022 and is projected to grow from USD 0.66 Billion in 2023 to USD 1.199 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.40% during the forecast period (2023 - 2030).
Segmental Overview
MRFR’s report includes an in-depth segmental analysis of the global primary cell market based on type, origin and end user.
Based on type, the market has been segmented into animal primary cells and human primary cells. Based on origin, the market has been segmented into hematopoietic cells, liver cells, renal cells, skeletal and muscle cells, skin cells, gastrointestinal cells, lung cells, heart and others. Based on end-user, the market has been segmented into life science research companies and research institutes.
Global Primary Cells Market: Regional Segmentation
Based on region, the market has been segmented into Europe, Americas, the Middle East and Africa (MEA), and Asia Pacific (APAC). The Americas cells market cover both South America and North America. The Europe primary cells market covers Eastern Europe and Western Europe. Key countries covered in the Asia Pacific primary cells market include China, South Korea, Japan, Australia, and India. In terms of revenue, North America and South America collectively dominate the global primary cells market. Some of the key factors supporting the growth of the market in Americas include strong government backing for RD, easy access to latest medical technologies and increased prevalence of cancer.
Europe in holds the second spot in terms of value. Healthcare remains a major area of focus for the EU. Over the years, several policies have been launched to improve health care services in the region. Advanced countries in Europe present attractive growth opportunities for market players.
APAC is viewed as an emerging market for primary cells. The healthcare sector in APAC is witnessing tremendous growth, which is translating into opportunities for market players. Rising number of cancer cases, introduction favourable policies and pharmaceutical outsourcing are some of the factors supporting the market growth in APAC. Spending on medical science RD institutes have surged in countries such as China and India, which is paving the way for the market to growth. The market in MEA is also expected to grow at a healthy pace but from a lower base. Many of the countries in MEA face issues such as underdeveloped healthcare infrastructure, limited access to services, etc.
Competitive Landscape
Some of the leading primary cells market players are, Cell Biologics (US), ZenBio, Inc. (US), ALLCells (US), Axol Biosciences (UK), Thermo Fisher Scientific (US), Merck KGaA (Germany), Lonza (Switzerland), American Type Culture Collection (ATCC) (US), Promocell (Germany) and STEMCELL Technologies (Canada).
For more information visit at MarketResearchFuture
